Herpes Simplex
Also known as: HSV, Eyes, Vision, Visual, Sight
Methodology & AI Transparency ⓘ
Herpes Simplex Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Herpes is an infection that is caused by a herpes simplex virus (HSV).
- 2 Real-world patient consensus: Mapped to Bacterial, Viral & Fungal Infections under ICD-10-CM B00.9 for Herpes Simplex clinical workups.
- 3 Typical cash cost range: Workup highlights for Herpes Simplex (B00.9): antimicrobial stewardship (narrow-spectrum in Herpes Simplex (B00.9: pathogen-directed duration) or).
- 4 Top reported side effects / signs: Follow-up benchmark in Herpes Simplex: maintaining Complete Blood Count in Herpes Simplex (B00.9: (WBC & Differential)) within WBC 4.0 – 10.0 x10^3/uL (B00.9).
Ask our AI Specialists anything about Herpes Simplex
What Is Herpes Simplex?
Herpes is an infection that is caused by a herpes simplex virus (HSV). Oral herpes causes cold sores around the mouth or face. Genital herpes affects the genitals, buttocks or anal area. Genital herpes is a sexually transmitted infection (STI). It affects the genitals, buttocks or anal area. Other herpes infections can affect the eyes, skin, or other parts of the body. The virus can be dangerous in newborn babies or in people with weak immune systems. There are two types of HSV: HSV type 1 most commonly causes cold sores. It can also cause genital herpes. HSV type 2 is the usual cause of genital herpes, but it also can infect the mouth.
Pathophysiology, Underlying Causes & Clinical Presentation
Underlying Herpes Simplex (code B00.9) is cytokine pyrogen release [Herpes Simplex B00.9], Cross-referenced with NIH MeSH (Herpes Simplex), which Bacterial, Viral & Fungal Infections clinicians address while surveilling Complete Blood Count in Herpes Simplex (B00.9: (WBC & Differential)) (WBC 4.0 – 10.0 x10^3/uL (B00.9)).
Common Symptoms & Clinical Signs
- • HSV type 1 most commonly causes cold sores. It can also cause genital herpes
- • HSV type 2 is the usual cause of genital herpes, but it also can infect the mouth
- • Presentation of Herpes Simplex (B00.9): painful vesicular rash in Herpes Simplex (B00.9: in a dermatomal)
- • Secondary Herpes Simplex clinical sign: regional lymph node in Herpes Simplex (B00.9: tenderness or acute)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Herpes Simplex Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | B00.9 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Bacterial, Viral & Fungal Infections | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Complete Blood Count in Herpes Simplex (B00.9: (WBC & Differential)) | WBC 4.0 – 10.0 x10^3/uL (B00.9) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: C-Reactive Protein / in Herpes Simplex (B00.9: Procalcitonin) | Resolution to baseline (B00.9) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Targeted PCR / in Herpes Simplex (B00.9: Culture & Sensitivity) | Pathogen clearance / negative test (B00.9) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Herpes Simplex
| Medication | Pharmacologic Class | Patient Worth-It | CMS NADAC / Unit | Typical Lowest Cash |
|---|---|---|---|---|
| Acyclovir Zovirax, Avaclyr • RxCUI 197311 | Herpes Simplex Virus Nucleoside Analog DNA Polymerase Inhibitor | 78% | $0.0962 | $ 6.30 /mo |
| Herz Homo (Herpes Zoster Nosode) Herz Homo • RxCUI RXN-B437421889 | Over-the-Counter Clinical Monograph | 86% | $2.3700 | $ 179.14 /mo |
| Acyclovir and Hydrocortisone Xerese • RxCUI 998422 | Herpes Simplex Virus Nucleoside Analog DNA Polymerase Inhibitor | 84% | $0.1070 | $ 12.83 /mo |
| Xerese (Acyclovir and Hydrocortisone) Xerese • RxCUI 998426 | Herpes Simplex Virus Nucleoside Analog DNA Polymerase Inhibitor | 93% | $0.1070 | $ 16.21 /mo |
| Hers Homo (Herpes Simplex I, Herpes Simplex Ii) Hers Homo • RxCUI RXN-B437421875 | Over-the-Counter Clinical Monograph | 88% | $2.6700 | $ 200.74 /mo |
| Zovirax (Acyclovir) Zovirax • RxCUI 307730-B01870994 | Herpes Simplex Virus Nucleoside Analog DNA Polymerase Inhibitor | 77% | $0.1070 | $ 6.30 /mo |
| Famciclovir Famvir • RxCUI 198382 | Herpes Simplex Virus Nucleoside Analog DNA Polymerase Inhibitor | 93% | $0.2120 | $ 10.46 /mo |
| Avaclyr (Acyclovir) Avaclyr • RxCUI 197311-B48102028 | Herpes Simplex Virus Nucleoside Analog DNA Polymerase Inhibitor | 93% | $0.1070 | $ 16.21 /mo |
| Valtrex (Valacyclovir Hydrochloride) Valtrex • RxCUI 313565-B01730933 | Herpes Simplex Virus Nucleoside Analog DNA Polymerase Inhibitor | 83% | $12.8051 | $ 9.27 /mo |
| Acyclovir Sodium Zovirax • RxCUI 1734932 | Herpes Simplex Virus Nucleoside Analog DNA Polymerase Inhibitor | 80% | $0.1070 | $ 6.30 /mo |
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Herpes Simplex)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Herpes zoster recurrence, and safety and immunogenicity of the recombinant zoster: What a 1,426-Participant Study Found In participants ≥50 years with prior HZ, RZV does not increase HZ recurrence risk. The Journal of infection • 2025-09-15 • Phase III Randomized Trial | N = 1,426 | 96/100 | PMID 40780591 ↗ |
| New Insights on A phase 3, randomized, gold-standard blind, compared against a dummy pill: What a 298-Participant Study Found Treatment-emergent side effects in both groups were generally mild in severity; there were two moderate events that were judged unrelated to study treatment, and no severe or serious events. The Journal of dermatology • 2023-03-15 • Phase III Randomized Trial | N = 298 | 93/100 | PMID 36353762 ↗ |
| Can This Approach Help? Inside the Latest Research on An Analysis of How Herpes Zoster Pain Affects Health-related Quality of Life of A total of 520 immunocompetent and 172 HSCT individuals with HZ were included. The Clinical journal of pain • 2023-08-01 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 37166199 ↗ |
| Can This Approach Help? Inside the Latest Research on Adjuvanted recombinant zoster vaccine decreases herpes zoster-associated pain and VE in reducing pain medication use (39.6%; P -value: 0.008) and duration of medication use (49.3%, P -value: 0.040) was reported in the ZOE-70 study; corresponding positive VE estimates were observed in the ZOE-50 and ZOE-HSCT... Pain • 2023-04-01 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 36066965 ↗ |
| Can This Approach Help? Inside the Latest Research on Ceftobiprole versus ceftriaxone ± linezolid in Community-Acquired Bacterial Ceftobiprole was non-inferior to ceftriaxone ± linezolid for clinical success at Day 3 according to the current 2020 FDA CABP Guidance. PloS one • 2025-01-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 40554538 ↗ |
Herpes Simplex Patient Community & “People Like Me” Threads
Filter Herpes Simplex community threads and patient logs by age, biological sex, dosage, and treatment duration.